Patriot Financial Group Insurance Agency LLC Invests $220,000 in Thermo Fisher Scientific Inc. $TMO

Key Points

• Patriot Financial Group has invested $220,000 in Thermo Fisher Scientific by acquiring 542 shares during Q2, highlighting continued institutional interest in the medical research company.
• CEO Marc N. Casper sold 10,000 shares at an average price of $500.96, reducing his ownership by 7.99%, while other insiders have also sold shares totaling over $14 million in the last 90 days.
• Analysts have a consensus rating of “Moderate Buy” on Thermo Fisher Scientific with an average price target of $585.37, following recent upgrades and revised price targets from various firms.

Patriot Financial Group Insurance Agency LLC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 542 shares of the medical research company's stock, valued at approximately $220,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC lifted its stake in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the period. Vest Financial LLC raised its holdings in Thermo Fisher Scientific by 73.4% during the 1st quarter. Vest Financial LLC now owns 3,188 shares of the medical research company's stock valued at $1,586,000 after buying an additional 1,349 shares during the last quarter. Impact Capital Partners LLC grew its holdings in Thermo Fisher Scientific by 7.3% in the 1st quarter. Impact Capital Partners LLC now owns 1,024 shares of the medical research company's stock worth $510,000 after acquiring an additional 70 shares during the last quarter. Finally, Sivia Capital Partners LLC raised its stake in shares of Thermo Fisher Scientific by 21.6% during the first quarter. Sivia Capital Partners LLC now owns 891 shares of the medical research company's stock valued at $443,000 after acquiring an additional 158 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday. Evercore ISI lowered their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Barclays raised their price target on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an "overweight" rating in a report on Thursday. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, William Blair began coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating on the stock. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $585.37.

Thermo Fisher Scientific Trading Up 3.6%

Shares of TMO stock opened at $543.88 on Monday. The stock has a market capitalization of $205.38 billion, a P/E ratio of 31.46, a P/E/G ratio of 2.95 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm's 50 day moving average is $482.58 and its 200 day moving average is $446.77. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period last year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.